Disease burden and risk factors of myocarditis among children and adolescents aged 0-19 years in China from 1990 to 2021 and projection of future disease burden trends

Lu-Hua ZHAO, Jing-Xiu ZHANG, Zhen-Zhen ZHAO, Wei WU

Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (8) : 998-1007.

PDF(1187 KB)
HTML
PDF(1187 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (8) : 998-1007. DOI: 10.7499/j.issn.1008-8830.2507141
CLINICAL RESEARCH

Disease burden and risk factors of myocarditis among children and adolescents aged 0-19 years in China from 1990 to 2021 and projection of future disease burden trends

Author information +
History +

Abstract

Objective Based on data from the Global Burden of Disease Study (GBD) 2021, this study aims to analyze trends in myocarditis among children and adolescents aged 0-19 years in China from 1990 to 2021 and predicts the disease burden trends from 2025 to 2050. Methods Data on incidence, prevalence, mortality, and disability-adjusted life year (DALY) of myocarditis in the Chinese population aged 0-19 years were extracted from the GBD 2021 database. Joinpoint regression was used to estimate annual percent change. The GBD comparative risk assessment framework was used to quantify four categories of risk factors: environmental/occupational risks, non-optimal temperature, high temperature, and low temperature. The ARIMA model was applied to forecast the disease burden trends from 2025 to 2050. Results From 1990 to 2021, the age-standardized prevalence rate of myocarditis in Chinese children and adolescents aged 0-19 years increased, while the age-standardized incidence rate, age-standardized DALY rate, and age-standardized mortality rate decreased. The overall disease burden in China exceeded the global average and that of regions with a middle socio-demographic index. Males had a higher disease burden than females. In 2021, non-optimal temperature and environmental/occupational risks collectively accounted for 66.4% of the disease burden, and DALYs and mortality attributable to high temperature showed an increasing trend. ARIMA model projections indicate that by 2050, the overall incidence of myocarditis will remain stable, whereas DALYs and mortality in the 5-9-year age group are expected to increase among Chinese children and adolescents aged 0-19 years. Conclusions In China, the age-standardized prevalence of myocarditis among children and adolescents aged 0-19 years increased continuously from 1990 to 2021, and males had higher values across all burden metrics than females. Projections for 2025-2050 suggest that the overall incidence of myocarditis will remain stable, whereas the disability and mortality burden in the 5-9-year age group will rise. An age- and sex-stratified prevention and control system should be established, and protection against extreme temperatures should be incorporated into the national strategy for children's cardiovascular health.

Key words

Myocarditis / Global Burden of Disease Study / Risk factor / Child

Cite this article

Download Citations
Lu-Hua ZHAO , Jing-Xiu ZHANG , Zhen-Zhen ZHAO , et al. Disease burden and risk factors of myocarditis among children and adolescents aged 0-19 years in China from 1990 to 2021 and projection of future disease burden trends[J]. Chinese Journal of Contemporary Pediatrics. 2026, 28(8): 998-1007 https://doi.org/10.7499/j.issn.1008-8830.2507141

References

[1]
Law YM, Lal AK, Chen S, et al. Diagnosis and management of myocarditis in children: a scientific statement from the American Heart Association[J]. Circulation, 2021, 144(6): e123-e135. DOI: 10.1161/CIR.0000000000001001 .
[2]
丛超, 郭义山, 王东. 病毒性心肌炎发病机制的研究进展[J]. 医学综述,  2017, 23(15): 2948-2953. DOI: 10.3969/j.issn.1006-2084.2017.15. 008 .
[3]
Alkan F, Bircan O, Can F, et al. Comparison of cardiac magnetic resonance and speckle tracking echocardiography in cardiac evaluation of children with acute myocarditis with preserved left ventricular function[J]. BMC Med Imaging, 2025, 25(1): 243. PMCID: PMC12219550. DOI: 10.1186/s12880-025-01772-4 .
[4]
Messroghli DR, Pickardt T, Fischer M, et al. Toward evidence-based diagnosis of myocarditis in children and adolescents: rationale, design, and first baseline data of MYKKE, a multicenter registry and study platform[J]. Am Heart J, 2017, 187: 133-144. DOI: 10.1016/j.ahj.2017.02.027 .
[5]
Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology[J]. J Am Coll Cardiol, 2015, 66(21): 2362-2371. DOI: 10.1016/j.jacc.2015.09.035 .
[6]
Yang C, Jia Y, Zhang C, et al. Global, regional, and national burdens of heart failure in adolescents and young adults aged 10-24 years from 1990 to 2021: an analysis of data from the Global Burden of Disease Study 2021[J]. EClinicalMedicine, 2025, 79: 102998. PMCID: PMC11683260. DOI: 10.1016/j.eclinm.2024.102998 .
[7]
Zhang YD, Chen N, Wang QY, et al. Global, regional, and national burden of myocarditis in children aged 0-14 years, 1990-2021: analysis for the Global Burden of Disease Study 2021[J]. Front Public Health, 2024, 12: 1504586. PMCID: PMC11695415. DOI: 10.3389/fpubh.2024.1504586 .
[8]
于君平, 王梦龙, 徐瑶, 等. 1990年和2019年中国人群心肌炎疾病负担研究[J]. 中华内科杂志, 2022, 61(11): 1247-1252. DOI: 10.3760/cma.j.cn112138-20211115-00812 .
[9]
Bao C, Shi L, Wen Y, et al. Trends in the incidence and mortality rates of myocarditis in the Chinese population during 1990-2019: joinpoint regression and age-period-cohort analysis[J]. Anatol J Cardiol, 2024, 28(3): 165-172. PMCID: PMC10918279. DOI: 10.14744/AnatolJCardiol.2023.3569 .
[10]
Zhang Y, Feng L, Zhu Z, et al. Global burden of myocarditis in youth and middle age (1990-2019): a systematic analysis of the disease burden and thirty-year forecast[J]. Curr Probl Cardiol, 2024, 49(9): 102735. DOI: 10.1016/j.cpcardiol.2024.102735 .
[11]
GBD 2021 Global AMD Collaborators. Global burden of vision impairment due to age-related macular degeneration, 1990-2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet Glob Health, 2025, 13(7): e1175-e1190. PMCID: PMC12208786. DOI: 10.1016/S2214-109X(25)00143-3 .
[12]
Chen C, You Y, Du Y, et al. Global epidemiological trends in the incidence and deaths of acute respiratory infections from 1990 to 2021[J]. Heliyon, 2024, 10(16): e35841. PMCID: PMC11367038. DOI: 10.1016/j.heliyon.2024.e35841 .
[13]
Wu G, Xu W, Wu S, et al. Global burden and attributable risk factors of inflammatory cardiomyopathy and myocarditis from 1990 to 2019[J]. Archives of Public Health, 2025, 83(1): 11. PMCID: PMC11726952. DOI: 10.1186/s13690-024-01473-4 .
[14]
Jiang B, Lin K, Buys N, et al. Trend and burden of suboptimal breastfeeding in children under five years of age in 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Nutrients, 2025, 17(7): 1134. PMCID: PMC11990223. DOI: 10.3390/nu17071134 .
[15]
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 385(9963): 117-171. PMCID: PMC4340604. DOI: 10.1016/S0140-6736(14)61682-2 .
[16]
林德荣, 李悦, 叶小琳, 等. 1990—2021年中国和全球脑出血疾病负担变化趋势与发病预测分析[J/OL]. 中国全科医学. (2025-04-17)[2025-07-22].
[17]
GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2162-2203. PMCID: PMC11120204. DOI: 10.1016/S0140-6736(24)00933-4 .
[18]
Burkart KG, Brauer M, Aravkin AY, et al. Estimating the cause-specific relative risks of non-optimal temperature on daily mortality: a two-part modelling approach applied to the Global Burden of Disease Study[J]. Lancet, 2021, 398(10301): 685-697. PMCID: PMC8387975. DOI: 10.1016/S0140-6736(21)01700-1 .
[19]
Wu Y, Xia F, Chen M, et al. Disease burden and attributable risk factors of neonatal disorders and their specific causes in China from 1990 to 2019 and its prediction to 2024[J]. BMC Public Health, 2023, 23(1): 122. PMCID: PMC9845098. DOI: 10.1186/s12889-023-15050-x .
[20]
Xu M, Tang C, Shen Y, et al. Analysis of the burden of intracerebral hemorrhage in the Asian population aged 45 and older and ARIMA model prediction trends: a systematic study based on the GBD 2021[J]. Front Neurol, 2025, 16: 1526524. PMCID: PMC11869383. DOI: 10.3389/fneur.2025.1526524 .
[21]
Popa A, Lazea C, Agoston-Coldea L. Novel insights on acute myocarditis in pediatric patients[J]. Eur Rev Med Pharmacol Sci, 2023, 27(23): 11479-11495. DOI: 10.26355/eurrev_202312_34587 .
[22]
Kang Z, Zhang L, Yang Z. Role of non-coding RNAs in the pathogenesis of viral myocarditis[J]. Virulence, 2025, 16(1): 2466480. PMCID: PMC11849450. DOI: 10.1080/21505594.2025.2466480 .
[23]
Goldberg JF, Spinner JA, Soslow JH. Myocarditis in children 2024, new themes and continued questions [J]. Curr Opin Cardiol, 2024, 39(4): 315-322. DOI: 10.1097/HCO.0000000000001151 .
[24]
Pasławska M, Grodzka A, Peczyńska J, et al. Role of miRNA in cardiovascular diseases in children-systematic review[J]. Int J Mol Sci, 2024, 25(2): 956. PMCID: PMC10816020. DOI: 10.3390/ijms25020956 .
[25]
Alahmad B, Khraishah H, Royé D, et al. Associations between extreme temperatures and cardiovascular cause-specific mortality: results from 27 countries[J]. Circulation, 2023, 147(1): 35-46. PMCID: PMC9794133. DOI: 10.1161/CIRCULATIONAHA.122.061832 .
[26]
Gostimirovic M, Novakovic R, Rajkovic J, et al. The influence of climate change on human cardiovascular function[J]. Arch Environ Occup Health, 2020, 75(7): 406-414. DOI: 10.1080/19338244.2020.1742079 .
[27]
Iba T, Helms J, Levi M, et al. Inflammation, coagulation, and cellular injury in heat-induced shock[J]. Inflamm Res, 2023, 72(3): 463-473. DOI: 10.1007/s00011-022-01687-8 .
[28]
李国雨, 郭峰, 汪琢, 等. 热习服对心血管系统的保护作用及其机制研究进展[J]. 生理学报, 2025, 77(5): 820-838. DOI: 10.13294/j.aps.2025.0050 .
[29]
Nakagawa Y, Inoue H, Shinone K, et al. Molecular biological analysis of cardiac effect of high temperature in rats[J]. Leg Med (Tokyo), 2012, 14(2): 63-68. DOI: 10.1016/j.legalmed.2011.12.001 .
[30]
Roths M, Freestone AD, Rudolph TE, et al. Environment-induced heat stress causes structural and biochemical changes in the heart[J]. J Therm Biol, 2023, 113: 103492. DOI: 10.1016/j.jtherbio.2023.103492 .
[31]
Zhou J, Lu X, Xie Y, et al. Clusterin activates the heat shock response via the PI3K/Akt pathway to protect cardiomyocytes from high-temperature-induced apoptosis[J]. Open Life Sci, 2025, 20(1): 20251082. PMCID: PMC11964181. DOI: 10.1515/biol-2025-1082 .
[32]
Sankoff J. Heat illnesses: a hot topic in the setting of global climate change[J]. Aust Fam Physician, 2015, 44(1-2): 22-26.
[33]
Quinn CM, Duran RM, Audet GN, et al. Cardiovascular and thermoregulatory biomarkers of heat stroke severity in a conscious rat model[J]. J Appl Physiol (1985), 2014, 117(9): 971-978. DOI: 10.1152/japplphysiol.00365.2014 .
[34]
Kang R, Nagoshi T, Kimura H, et al. Possible association between body temperature and B-type natriuretic peptide in patients with cardiovascular diseases[J]. J Card Fail, 2021, 27(1): 75-82. DOI: 10.1016/j.cardfail.2020.08.012 .
[35]
Bäck M, Hofmann R. Myocardial infarction and low ambient temperature: does presence or absence of stenoses make a difference?[J]. Eur Heart J, 2025, 46(5): 451-453. DOI: 10.1093/eurheartj/ehae820 .
[36]
Huang J, He Q, Jiang Y, et al. Low ambient temperature and incident myocardial infarction with or without obstructive coronary arteries: a Chinese nationwide study[J]. Eur Heart J, 2025, 46(5): 439-450. DOI: 10.1093/eurheartj/ehae711 .
[37]
Achebak H, Rey G, Lloyd SJ, et al. Ambient temperature and risk of cardiovascular and respiratory adverse health outcomes: a nationwide cross-sectional study from Spain[J]. Eur J Prev Cardiol, 2024, 31(9): 1080-1089. DOI: 10.1093/eurjpc/zwae021 .
[38]
Liang J, Yin K, Cao X, et al. Attenuation of low ambient Temperature-induced myocardial hypertrophy by atorvastatin via promoting BCL-2 expression[J]. Cell Physiol Biochem, 2017, 41(1): 286-295. DOI: 10.1159/000456111 .
[39]
D'Amato M, Molino A, Calabrese G, et al. The impact of cold on the respiratory tract and its consequences to respiratory health[J]. Clin Transl Allergy, 2018, 8: 20. PMCID: PMC6031196. DOI: 10.1186/s13601-018-0208-9 .
[40]
Williams JL, Jacobs HM, Lee S. Pediatric myocarditis[J]. Cardiol Ther, 2023, 12(2): 243-260. PMCID: PMC10008072. DOI: 10.1007/s40119-023-00309-6 .
[41]
Li J, Fan H, Yang Y, et al. Global burden of myocarditis from 1990 to 2021: findings from the Global Burden of Disease Study 2021[J]. BMC Cardiovasc Disord, 2024, 24(1): 720. PMCID: PMC11660449. DOI: 10.1186/s12872-024-04402-z .
[42]
Huber SA, Kupperman J, Newell MK.Hormonal regulation of CD4+ T-cell responses in coxsackievirus B3-induced myocarditis in mice[J]. J Virol, 1999, 73(6): 4689-4695. PMCID: PMC112510. DOI: 10.1128/JVI.73.6.4689-4695.1999 .
[43]
Huber SA.Coxsackievirus B3-induced myocarditis: infection of females during the estrus phase of the ovarian cycle leads to activation of T regulatory cells[J]. Virology, 2008, 378(2): 292-298. PMCID: PMC2596296. DOI: 10.1016/j.virol.2008.05.015 .

Footnotes

所有作者均声明无利益冲突。

PDF(1187 KB)
HTML

Accesses

Citation

Detail

Sections
Recommended

/